publication . Article . 2017

Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis

Jorge Pedrosa; Jorge Pedrosa; Patrícia Figueiredo; Ermei Mäkilä; Jouni Tapio Hirvonen; Alexandra Fraga; Alexandra Fraga; Nuno Vale; Nuno Vale; Nuno Vale; ...
Open Access English
  • Published: 01 Feb 2017
  • Publisher: Elsevier
  • Country: Portugal
Abstract
Fundação para a Ciência e Tecnologia (FCT, Portugal) and FEDER (European Union) for funding through UID/MULTI/04378/2013, project grant IF/00092/2014 and IF2014 position. Thanks are also due to “Comissão de Coordenação e Desenvolvimento Regional do Norte (CCDR-N)/NORTE2020/Portugal 2020” for funding through project DESignBIOtechHealth (ref. Norte-01-0145-FEDER-000024). H.A.S. acknowledges financial support from the Academy of Finland (decision nos. 252215 and 281300), the University of Helsinki Research Funds, the Biocentrum Helsinki, and the European Research Council under the European Union’s Seventh Framework Programme (FP/2007–2013, Grant No. 310892). The co...
Persistent Identifiers
Subjects
Medical Subject Headings: technology, industry, and agriculture
free text keywords: Ethionamide, Porous silicon nanoparticles, Mycobacterium tuberculosis, Strain H37Rv, MIC50, Ciências Médicas::Medicina Básica, Science & Technology, ta1182, ta116, ta114, Chemistry, medicine.drug, medicine, Conjugated system, Conjugate, Carboxylic acid, chemistry.chemical_classification, biology.organism_classification, biology, Stereochemistry, Nanoparticle, Combinatorial chemistry, Mesoporous material, Solubility
Funded by
AKA| Porous Silicon Nanodelivery Systems For Enhanced Targeted Cancer Therapy (NANOPSi-CAN)
Project
  • Funder: Academy of Finland (AKA)
  • Project Code: 281300
,
AKA| Porous Silicon Nanodelivery Systems For Enhanced Targeted Cancer Therapy (NANOPSi-CAN)
Project
  • Funder: Academy of Finland (AKA)
  • Project Code: 252215
,
FCT| UID/Multi/04378/2013
Project
UID/Multi/04378/2013
Applied Molecular Biosciences Unit
  • Funder: Fundação para a Ciência e a Tecnologia, I.P. (FCT)
  • Project Code: 147258
  • Funding stream: 5876
,
EC| POROUS SILICON NANOV
Project
POROUS SILICON NANOV
Multistage-Multifunctional Porous Silicon Nanovectors for Directed Theranostics
  • Funder: European Commission (EC)
  • Project Code: 310892
  • Funding stream: FP7 | SP2 | ERC
29 references, page 1 of 2

1. Siegel RL, Miller KD, Jemal A. CA Cancer J Clin. 2015;65:5.

2. Hait WN. Nat Rev Drug Discov. 2010;9:253.

3. Laurenzo D, Mousa SA. Acta Trop. 2011;111:5.

4. Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA. Int J Tuberc Lung Dis. 2016;20:1099.

5. Palomino JC, Martin A. Antibiotics. 2014;3:317.

6. Banerjee A, Dubnau E, Quemard A, et al. Science. 1994;263:227.

7. Johnsson K, King DS, Schultz PG. J Am Chem Soc. 1995;117:5009.

8. Baulard A, Betts JC, Engohang-Ndong J, et al. J Biol Chem. 2000;275:28326.

9. Francois AA, Nishida CR, Montellano PO, Phillips IR, Shephard EA. Drug Metab Disp. 2009;37:178.

10. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE. Proc Natl Acad Sci USA. 2000;97:9677.

11. Vilchèze C, Weisbrod TR, Clen B, et al. Antimicrob Agents Chemother. 2005;49:708.

12. Dodge AG, Richman JE, Johnson G, Wackett LP. Appl Environ Microbiol. 2006;72:7468.

13. Dover LG, Alahari A, Gratraud P, et al. Antimicrob Agents Chemother. 2007;51:1055.

14. Hanoulle X, Wieruszeski JM, Rousselot-Pailley P, et al. J Antimicrob Chemother. 2006;58:768.

15. Hanoulle X, Wieruszeski JM, Rousselot-Pailley P, Landrieu I, Baulard AR, Lippens G. Biochem Biophys Res Commun. 2005;331:452.

29 references, page 1 of 2
Any information missing or wrong?Report an Issue